Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TEAD transcription factor family comprises highly conserved DNA-binding proteins (TEAD1, TEAD3, TEAD4) that regulate gene expression via interaction with coactivators—primarily YAP and TAZ—in the Hippo signaling pathway. They control cell proliferation, differentiation, and organ size during development. In adult tissues, TEAD activity sustains stem cell populations and influences regeneration. Aberrant TEAD activity, often driven by dysregulated Hippo pathway, contributes to oncogenesis by promoting EMT, cellular proliferation, and survival. TEAD proteins interact with other signaling inputs, including TGF-β and SMADs, impacting fibrosis and cancer progression. Targeting the TEAD-YAP/TAZ interface is an emerging strategy in drug discovery, although direct pharmacological inhibition remains challenging due to the transcriptional nature of the proteins.
Inhibitors disrupt the TEAD-YAP/TAZ interaction, preventing the transcription of pro-growth and survival genes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TEA domain transcription factor 1, TEA domain transcription factor 3, and TEA domain transcription factor 4 (TEAD1, TEAD3, TEAD4).